ImmunityBio, Inc. (IBRX) — Institutional Holders, Q2 2026 (page 5)
405 institutional investment managers reported a IBRX position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $1.8B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 401 to 405. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
IBRX 13F holders ranked 401–405 of 405
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 401 | MARYLAND CAPITAL ADVISORS#401 · 3 sh | 3 | $27.00 | — | — |
| 402 | Hughes Financial Services#402 · 1 sh | 1 | $9.00 | 0.00% | 0.0% |
| 403 | Navigoe#403 · 2 sh | 2 | $0.00 | 0.00% | New |
| 404 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#404 · 410,655 sh | 410,655 | — | — | +6.3% |
| 405 | VESTOR CAPITAL#405 · 44,835 sh | 44,835 | — | — | +288.7% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.